ARMO BioSciences to Present at the Jefferies Immuno-Oncology Summit

Redwood City, CA, March 28, 2016 —ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that the company’s President and Chief Executive Officer Peter Van Vlasselaer, PhD will present at the following upcoming investor conference:

Event: Jefferies Immuno-Oncology Summit
Date: Friday, April 8, 2016
Time: 11:50 AM - 12:15 PM Eastern Time (8:50 AM - 9:15 AM Pacific Time)
Location: Boston Harbor Hotel, Boston, MA

About ARMO BioSciences

Founded in 2012, ARMO BioSciences is a clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications. The company’s lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. ARMO plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors. The company also has a robust pipeline of therapeutic cytokines and an anti-PD-1 checkpoint inhibitor.

For more information, please visit


ARMO BioSciences
Scott Ogg, PhD
Vice President Corporate Development and Operations